{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:53:57Z","timestamp":1785293637994,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,7]]},"DOI":"10.7759\/cureus.83681","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T23:11:37Z","timestamp":1746659497000},"source":"Crossref","is-referenced-by-count":3,"title":["Clinical Profile and Outcome of Patients With Advanced Hepatocellular Carcinoma (HCC) Taking Sorafenib or Lenvatinib: Real-World Experience From a Low-Middle Resource Country"],"prefix":"10.7759","author":[{"given":"Kinza","family":"Sabir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawayria","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nauman I","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barak","family":"Waris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx030","article-title":"Annual report to the nation on the status of cancer, 1975-2014, featuring survival","volume":"109","author":"Jemal A","year":"2017","unstructured":"Jemal A, Ward EM, Johnson CJ, et al.. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017, 109:djx030. 10.1093\/jnci\/djx030","journal-title":"J Natl Cancer Inst"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh SP","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025, 15:102446. 10.1016\/j.jceh.2024.102446","journal-title":"J Clin Exp Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh MR","year":"2023","unstructured":"Toh MR, Wong EY, Wong SH, Ng AW, Loo LH, Chow PK, Ngeow J. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023, 164:766-82. 10.1053\/j.gastro.2023.01.033","journal-title":"Gastroenterology"},{"key":"ref4","article-title":"Hepatocellular Carcinoma","author":"Asafo-Agyei KO","year":"2025","unstructured":"Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"D'souza S","year":"2020","unstructured":"D'souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020, 26:5759-83. 10.3748\/wjg.v26.i38.5759","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata M","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, et al.. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017, 11:317-70. 10.1007\/s12072-017-9799-9","journal-title":"Hepatol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S312748","article-title":"Sorafenib in the treatment of virus-related HCC: differences between HCV and HBV","volume":"14","author":"De Matteis S","year":"2021","unstructured":"De Matteis S, Ghetti M, Gramantieri L, Marisi G, Casadei-Gardini A. Sorafenib in the treatment of virus-related HCC: differences between HCV and HBV. Onco Targets Ther. 2021, 14:4305-8. 10.2147\/OTT.S312748","journal-title":"Onco Targets Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.35106","article-title":"Relative importance of hepatitis B and C viruses in hepatocellular carcinoma in EMRO countries and the Middle East: a systematic review","volume":"16","author":"Alavian SM","year":"2016","unstructured":"Alavian SM, Haghbin H. Relative importance of hepatitis B and C viruses in hepatocellular carcinoma in EMRO countries and the Middle East: a systematic review. Hepat Mon. 2016, 16:e35106. 10.5812\/hepatmon.35106","journal-title":"Hepat Mon"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim DW","year":"2017","unstructured":"Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017, 8:256-65. 10.21037\/jgo.2016.09.07","journal-title":"J Gastrointest Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2022.01061","article-title":"The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update","volume":"16","author":"Wen N","year":"2022","unstructured":"Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022, 16:20-30. 10.5582\/bst.2022.01061","journal-title":"Biosci Trends"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5942306","article-title":"Hepatocellular carcinoma in Pakistan: national trends and global perspective","volume":"2016","author":"Hafeez Bhatti AB","year":"2016","unstructured":"Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular carcinoma in Pakistan: national trends and global perspective. Gastroenterol Res Pract. 2016, 2016:5942306. 10.1155\/2016\/5942306","journal-title":"Gastroenterol Res Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520946872","article-title":"Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis","volume":"48","author":"Gu W","year":"2020","unstructured":"Gu W, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. J Int Med Res. 2020, 48:300060520946872. 10.1177\/0300060520946872","journal-title":"J Int Med Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00967-4","article-title":"Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions","volume":"21","author":"Mak LY","year":"2024","unstructured":"Mak LY, Liu K, Chirapongsathorn S, et al.. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024, 21:834-51. 10.1038\/s41575-024-00967-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita T","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, et al.. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020, 55:113-22. 10.1007\/s00535-019-01642-1","journal-title":"J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00110-2","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo M","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al.. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018, 391:1163-73. 10.1016\/S2468-1253(21)00110-2","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2013.11.003","article-title":"Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study","volume":"7","author":"Naqi N","year":"2014","unstructured":"Naqi N, Ahmad S, Murad S, Khattak J. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study. Hematol Oncol Stem Cell Ther. 2014, 7:27-31. 10.1016\/j.hemonc.2013.11.003","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.51253\/pafmj.v73i4.7889","article-title":"Adverse event profile in advanced hepatocellular carcinoma treated with sorafenib presenting to CMH Rawalpindi","volume":"73","author":"Masood M","year":"2023","unstructured":"Masood M, Nadeem M, Ali A, et al.. Adverse event profile in advanced hepatocellular carcinoma treated with sorafenib presenting to CMH Rawalpindi. Pak Armed Forces Med J. 2023, 73:1071-4. 10.51253\/pafmj.v73i4.7889","journal-title":"Pak Armed Forces Med J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366908-clinical-profile-and-outcome-of-patients-with-advanced-hepatocellular-carcinoma-hcc-taking-sorafenib-or-lenvatinib-real-world-experience-from-a-low-middle-resource-country","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T23:11:37Z","timestamp":1746659497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366908-clinical-profile-and-outcome-of-patients-with-advanced-hepatocellular-carcinoma-hcc-taking-sorafenib-or-lenvatinib-real-world-experience-from-a-low-middle-resource-country"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.83681","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}